Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Jamieson Wellness Inc yesterday and set a price target of C$42.00.
Meet Your ETF AI Analyst
Discover how TipRanks’ ETF AI Analyst can help you make smarter investment decisions
Explore ETFs TipRanks’ users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Keywood is an analyst with an average return of -6.1% and a 44.38% success rate. Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, DRI Healthcare, and Cipher Pharmaceuticals.
In a report released on November 2, TR | OpenAI – 4o also upgraded the stock to a Buy with a C$38.00 price target.
Based on Jamieson Wellness Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of C$199.11 million and a net profit of C$13.07 million. In comparison, last year the company earned a revenue of C$184.81 million and had a net profit of C$8.65 million
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JWEL in relation to earlier this year.
Jamieson Wellness Inc (JWEL) Receives a Buy from Stifel Nicolaus
